Cellerant Therapeutics, Inc.

The company is focused on haematopoietic stem cell-based therapeutics.

Cellerant Therapeutics Inc. is a biotechnology company that has licensed stem cell isolation and purification technology from Novartis. Cellerant was
founded by Dr. Irving Weissman, Director of the Cancer/Stem Cell Institute at Stanford University. Two products are yet in clinical development.
In May 2005, Cellerant has raised $16 million in a series B financing led by Novel Bioventures, but also including George Rathmann, CX Venture Group, Allen & Company and MPM.

Bruce Cohen, President & CEO
Raymond J. Tesi, M.D.
Ram Mandalam, Ph.D.
Linda Rogers
Lane Welton
Pattie Chiang

David Baltimore, Ph.D., President
Richard Chyette, Corporate Counsel/Secretary
Bruce Cohen, President & CEO
Stephen D. Greenberg, Managing Director
Dennis Henner, Ph.D.
Antoun Nabhan,
George B. Rathmann, Ph.D.
Irving L. Weissman, M.D.

James P. Allison, Ph.D., Professor of Immunology
Mark M. Davis, Ph.D., Professor of Microbiology and Immunology
Philip D. Greenberg, M.D., Professor of Medicine Leroy Hood, M.D., Ph.D.,
Stanley R. Riddell, M.D., Associate Professor
Irving L. Weissman, M.D. (Chair), Professor of Cancer Biology

Cellerant Therapeutics, Inc.
1531 Industrial Road
San Carlos, CA 94070
USA
Phone: +1-650-232-2122
Fax: +1-650-232-5495

Cellerant is developing a method for the purification of adult stem cells (haematopoietic stem cells (HSCs) from peripheral blood) in order to use them in stem cell transplantations to treat cancer patients after chemotherapy and radiation. HP-HSC (highly-purified HSC) transplants are also expected to treat a variety of haematologic disorders and autoimmune diseases, like Lupus, Crohn’s disease, rheumatoid arthritis, multiple sclerosis and type I diabetes. Advantages of the highly purified CD34+CD90+ cell product are that the product does not cause Graft-versus-host disease (GVHD) and that it can be from haploidentical donors.

The MP Cell product line contains myeloid progenitor cells that are more committed to the myeloid lineage. That means that MP Cells do not engraft and do not self-renew, what results in the production of mature myeloid cells for only a certain period of time. After that time, the cells become cleared from the patient.

Both products are currently in clinical development.

Cellerant has lisenced a patent portfolio that includes eleven issued US, European, and Japanese patents.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.